Stromatt Scott C 4
4 · Aptevo Therapeutics Inc. · Filed Mar 13, 2018
Insider Transaction Report
Form 4
Stromatt Scott C
Chief Medical Officer and SVP
Transactions
- Exercise/Conversion
Restricted Stock Unit
2018-03-09−13,892→ 16,269 total→ Common Stock (13,892 underlying) - Exercise/Conversion
Common Stock
2018-03-09+13,892→ 204,737 total - Award
Employee Stock Options (Right to Buy)
2018-03-09+67,400→ 67,400 totalExercise: $3.13Exp: 2028-03-09→ Common Stock (67,400 underlying)
Footnotes (3)
- [F1]Each RSU converts into the Issuer's common stock on a one-for-one basis.
- [F2]On March 9, 2018, the reporting person was granted 67,400 stock options vesting in three equal annual installments beginning on the first anniversary of the grant date.
- [F3]The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 10, 2015. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016, each RSU was adjusted and assumed by the Issuer. The RSUs fully vested as of March 9, 2018.